TWST News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.t

(NASDAQ:TWST) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025. T

(NASDAQ:TWST) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL). “With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics,” said Emily M. Leproust, Ph.D., CEO and co-founder o

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. “We desi

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. “A strong balance sheet and disciplined cost-management underpin our focused business execution,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the “Company” ta

Twist Bioscience's Q4 results topped estimates, with revenue up 27% YoY. Fiscal 2025 guidance includes revenue growth and a targeted gross margin of 48%.

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will report an earnings per share (EPS) of $-1.28.